Foreign Drug Makers Consider Japanese Market More Important Than Japanese Drug Companies
This article was originally published in PharmAsia News
According to a recent survey conducted by Booz & Company on the pharmaceutical industry for the next 10 years in Japan, 38 percent of foreign pharmaceutical companies operating in Japan consider the Japanese market very important to them. In contrast, 27 percent of Japanese major pharmaceutical companies and 18 percent of middle sized drug makers share the same view. Among the major Japanese drug makers, 36 percent plans to focus on overseas market. Out of 248 target foreign and Japanese domestic companies, 35 companies answered the survey. (Click here for more - Japanese language
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.